AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. [electronic resource]
Producer: 20120605Description: 2997-3005 p. digitalISSN:- 1097-0215
- Animals
- Antineoplastic Agents -- pharmacology
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Aurora Kinase B
- Aurora Kinases
- Benzimidazoles -- pharmacology
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Docetaxel
- Humans
- Lymphoma, B-Cell -- drug therapy
- Lymphoma, Mantle-Cell -- drug therapy
- Mice
- Mice, SCID
- Protein Kinase Inhibitors -- pharmacology
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Taxoids -- pharmacology
- Urea -- analogs & derivatives
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.